Pharmacodynamic effects during the transition between cangrelor and ticagrelor.

Author: AgarwalZubin, GogoProspero, KeatingFriederike K, SchneiderDavid J, SeecheranNaveen

Paper Details 
Original Abstract of the Article :
OBJECTIVES: This study sought to determine pharmacodynamic effects during transition from intravenous cangrelor to oral ticagrelor and from oral ticagrelor to intravenous cangrelor. BACKGROUND: Cangrelor is an intravenous antagonist of P2Y12 and its use will require transition to and from oral agen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.jcin.2013.08.017

データ提供:米国国立医学図書館(NLM)

Switching Medications: Navigating the Transition Between Cangrelor and Ticagrelor

The world of cardiovascular medicine is like a vast desert, with many different paths leading to treatment. This study focuses on a specific journey, the transition between two antiplatelet drugs, cangrelor and ticagrelor. The authors explored the pharmacodynamic effects of switching between these medications, which can be tricky, like navigating a shifting sand dune. They found that ticagrelor can be safely administered during cangrelor infusion, offering flexibility in treatment strategies. This is valuable information for clinicians, like finding a reliable guide in a treacherous landscape.

A Smooth Transition: Ensuring Patient Safety During Medication Changes

The study provides valuable insight into the dynamic interplay between these two drugs, ensuring a safe transition for patients. This information is particularly relevant for clinicians who need to manage patients requiring both intravenous and oral antiplatelet therapy. By understanding the pharmacodynamic effects, clinicians can better anticipate and address potential risks, like a skilled traveler anticipating changes in the desert environment.

A Roadmap for Cardiovascular Care

The findings of this study, like a well-marked trail in the desert, provide clinicians with a better understanding of the pharmacodynamic effects of switching between cangrelor and ticagrelor. This knowledge allows for safer and more effective treatment strategies for patients, ultimately contributing to improved cardiovascular health.

Dr. Camel's Conclusion

This research sheds light on the safe transition between cangrelor and ticagrelor, providing clinicians with a roadmap for navigating medication changes in cardiovascular care. By understanding the pharmacodynamic interactions between these drugs, we can better protect our patients and optimize their treatment outcomes, like a seasoned traveler guiding a caravan through the desert.

Date :
  1. Date Completed 2014-12-12
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24656538

DOI: Digital Object Identifier

10.1016/j.jcin.2013.08.017

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.